These findings warrant further investigation on the role of GSIs in muscle-wasting conditions, in particular instances in which tumor-suppressing drugs (Rapamycin, API-1) are used, or where MPS rates are reduced, as GSIs may elevate MPS and help to sustain skeletal muscle mass. This evidence concerns the gene BIRC2 and neoplasm.